| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
5,832 |
3,857 |
$1.32M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
4,155 |
3,402 |
$1.11M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,013 |
12,715 |
$750K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,796 |
9,355 |
$369K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,565 |
4,045 |
$350K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,826 |
1,414 |
$148K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,845 |
2,451 |
$140K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,906 |
2,440 |
$76K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,513 |
5,980 |
$67K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,067 |
940 |
$66K |
| 99051 |
|
9,045 |
7,731 |
$53K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
4,266 |
3,429 |
$53K |
| 87581 |
|
4,305 |
3,420 |
$49K |
| 87486 |
|
4,755 |
3,438 |
$48K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,515 |
2,036 |
$40K |
| 99215 |
Prolong outpt/office vis |
543 |
489 |
$37K |
| 86328 |
|
998 |
872 |
$29K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
147 |
73 |
$19K |
| 99205 |
Prolong outpt/office vis |
200 |
181 |
$19K |
| 71046 |
Radiologic examination, chest; 2 views |
1,015 |
782 |
$14K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
343 |
287 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,328 |
2,158 |
$6K |
| 86769 |
|
161 |
136 |
$5K |
| 87807 |
|
455 |
394 |
$4K |
| 81003 |
|
2,471 |
1,924 |
$3K |
| 74019 |
|
135 |
118 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,301 |
1,057 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
1,007 |
718 |
$950.64 |
| 81025 |
|
196 |
135 |
$773.68 |
| 36416 |
|
1,209 |
886 |
$703.96 |
| 74018 |
|
30 |
29 |
$552.45 |
| 94760 |
|
1,010 |
782 |
$391.52 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14 |
12 |
$337.67 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
47 |
39 |
$305.75 |
| 81002 |
|
105 |
86 |
$200.35 |
| 87809 |
|
25 |
12 |
$132.60 |
| H0033 |
Oral medication administration, direct observation |
33 |
29 |
$75.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
33 |
27 |
$35.84 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
71 |
45 |
$12.81 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
30 |
24 |
$11.77 |
| 99000 |
|
2,796 |
1,926 |
$6.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
47 |
29 |
$0.36 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
61 |
39 |
$0.00 |
| 76140 |
|
30 |
18 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
14 |
13 |
$0.00 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
18,391 |
13,827 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
74 |
64 |
$0.00 |